PORCN and colorectal cancer: RNF43 loss-of-function mutations are often detected in MSI-type colorectal cancer, and PORCN inhibitor, which can inhibit ligand-mediated activation of the Wnt/β-catenin cascade, can effectively inhibit the progression of RNF43-mutant cell-derived PDX colorectal cancer in vivo [12].